Company Kronos Bio, Inc.

Equities

KRON

US50107A1043

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 02:56:32 2024-03-28 pm EDT 5-day change 1st Jan Change
1.32 USD +6.45% Intraday chart for Kronos Bio, Inc. +10.00% +5.60%

Business Summary

Kronos Bio, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics that target the deregulated transcription that causes cancer and other serious diseases. It is developing KB-0742, its internally discovered oral cyclin dependent kinase 9 (CDK9) inhibitor, for the treatment of MYC-amplified and others transcriptionally addicted solid tumors. It has initiated the Phase 2 portion of its Phase 1/2 clinical trial for KB-0742. It is also developing KB-9558, which inhibits the lysine acetyltransferase (KAT) domain of p300, a critical node of the IRF4 TRN. IRF4 is a key transcription factor driver in multiple myeloma and KB-9558 selectively targets its activity. Its scientific focus is on developing medicines that target deregulated transcription, the hallmark of cancer and other serious diseases. Using its Small Molecule Microarray (SMM) platform or other approaches, it can generate and advance small molecule starting points into drug development candidates.

Number of employees: 63

Managers

Managers TitleAgeSince
Chief Executive Officer 68 18-03-31
Founder 47 17-06-01
Founder 52 17-06-01
Director of Finance/CFO 58 23-09-14
Chief Tech/Sci/R&D Officer 59 22-01-31
Corporate Officer/Principal - 20-04-30
Corporate Officer/Principal - 20-12-31

Members of the board

Members of the board TitleAgeSince
Founder 52 17-06-01
Founder 47 17-06-01
Founder 74 17-06-01
Director/Board Member 70 21-03-24
Director/Board Member 44 20-09-14
Director/Board Member 49 20-12-31
Director/Board Member 68 23-04-19
Director/Board Member 51 23-04-09

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 60,095,013 46,547,485 ( 77.46 %) 0 77.46 %

Shareholders

NameEquities%Valuation
7,445,248 12.77 % 8 M $
Omega Fund Management LLC
6.548 %
3,818,283 6.548 % 4 M $
BVF, Inc.
4.982 %
2,905,043 4.982 % 3 M $
VV Manager LLC
4.742 %
2,765,314 4.742 % 3 M $
Perceptive Advisors LLC
3.006 %
1,752,745 3.006 % 2 M $
Vanguard Global Advisers LLC
2.916 %
1,700,677 2.916 % 2 M $
Partners Capital Investment Group LLP
2.856 %
1,665,797 2.856 % 2 M $
1,438,232 2.466 % 1 M $
Wildcat Capital Management LLC
2.226 %
1,297,959 2.226 % 1 M $
BlackRock Advisors LLC
1.613 %
940,696 1.613 % 978 324 $

Company contact information

Kronos Bio, Inc.

1300 So. El Camino Real Suite 300

94402, San Mateo

+

http://www.kronosbio.com
address Kronos Bio, Inc.(KRON)